Xandr Furthers Integrations with Industry IDs and Advances Proprietary Modelled and Contextual Solutions
27.10.2021 15:00:00 EEST | Business Wire | Press release
Xandr, AT&T’s advanced advertising company, today announced investments which expand its portfolio of identity offerings. Earlier this year, Xandr announced a multi-faceted approach to balance customers’ advertising needs and consumer privacy, and has now delivered several addressability solutions through integrations with LiveRamp (NYSE:Ramp), netID and Unified ID 2.0, as well as publisher first-party data activation solutions, contextual and modelled capabilities.
Facilitating addressability through consumer-consented data is a key component that Xandr has made strides on. Through Xandr’s collaboration with LiveRamp, Xandr this year launched end-to-end support for RampID on its platform. Publishers using Xandr’s Monetize SSP have started to use RampIDs in their monetization strategies and have seen positive indications. Agencies and marketers are also beginning alpha tests for RampID capabilities on Xandr’s Invest DSP, which include data onboarding, targeting and measurement. Xandr and LiveRamp are also expanding their relationship in other ways, including LiveRamp becoming a partner on Xandr Curate, the platform for monetizing data through curated deals. Travis Clinger, SVP, addressability and ecosystem at LiveRamp comments: “Our mission has always been to make it safe and easy for our partners and customers to connect data, wherever data lives. Our continued and evolving partnership with Xandr helps make that possible programmatically, bringing the demand- and sell-sides closer together to ensure critical advertising workflows are more sustainable, efficient, and performant on a global scale. Further, Xandr's support of RampID, a high-fidelity, person-level, omnichannel identifier, takes our existing integration with them to the next level.”
First-party data will be key in the new era of advertising. Xandr has laid the foundation to roll out a suite of powerful tools which empower publishers to leverage their data assets to power relevant advertising, while still protecting the privacy needs of their users. Xandr’s publisher first-party data capabilities provide the necessary targeting, frequency management and privacy controls to enable scaled monetization across environments. Today, Xandr supports netID across multiple use cases, and continues to build upon this investment, working with netID, publishers and marketers on its platform. In 2022, Xandr will launch an enhanced Publisher ID suite providing additional capabilities, which is built to address publishers’ forward-looking needs. “Providing publishers with the right tools to successfully execute business models, while ensuring that data is properly protected and users are in full control, will be of the utmost importance in this transformational shift in advertising”, says Achim Schlosser, CTO of the European netID Foundation. “First-party data is a key building block in future of digital marketing, which needs to be both user-friendly and sustainable. For that we need strong co-operation among the industry to enable a fair and open web.”
Whilst LiveRamp and netID integrations are complete, Xandr is collaborating with the industry to ensure readiness for the broader launch of the Unified ID 2.0 integration.
Alongside these integrations Xandr has advanced its modelled and contextual solutions utilizing data science, machine learning, and contextual data to enable relevant advertising in the absence of identifiers.
Xandr has been productizing its Real Time Signals offering (RTS) which enables audience activation by using contextual signals such as hyperlocal geolocation and URL to reach audiences in identity-less environments. RTS is a differentiating, scalable way to reach our clients’ desired customers in a privacy compliant manner and Xandr recently showcased this through its work with Dentsu.
Frequency management to avoid over-exposure is a critical need for publishers and marketers. As such, Xandr has developed an inventory classification model which does not rely on cookies or device/user level identifiers. This enables Xandr to infer one brand’s ad exposure to a user based on averages in real-time and make decisions on whether or not to bid for an impression, thereby enabling platform customers to prevent consumer ad fatigue and wasted spend without reliance on user identifiers.
Xandr understands that collaboration in the industry is the best approach to solving identity. With this in mind Xandr participated in the Google FLoC trial in June and July to better understand the solution. Xandr is continuing to work across industry groups to refine and test other proposals within this, including PARAKEET.
“Xandr is focused on the development of alternative solutions for its clients. Whilst integrations are an important part of this, as is first-party data activation solutions, Xandr is also heavily focused on offering modelled and contextual solutions of its own. During this time Xandr has also been working with customers on different testing opportunities and on Xandr’s platform, buyers and sellers are now able to target, frequency cap and measure outcomes” adds Ewa Maciukiewicz, VP, Product Management, Xandr. “Whilst there is no simple solution to identity, looking ahead to 2022 Xandr is focused on scaling addressability, simplifying first-party data activation, accelerating the connection between marketers and publishers, and thinking beyond identity to drive relevant advertising in non-addressable environments.”
ABOUT XANDR
A business unit within AT&T, Xandr powers a global marketplace for premium advertising. Our data-enabled technology platform, encompassing Xandr Invest and Xandr Monetize, optimizes return on investment for both buyers and sellers. For more than 143 years, AT&T has used data and technology to inform and improve the consumer experience.
ABOUT LiveRamp
LiveRamp is the leading data connectivity platform for the safe and effective use of data. Powered by core identity resolution capabilities and an unparalleled network, LiveRamp enables companies and their partners to better connect, control, and activate data to transform customer experiences and generate more valuable business outcomes. LiveRamp’s fully interoperable and neutral infrastructure delivers end-to-end addressability for the world’s top brands, agencies, and publishers. For more information, visit www.LiveRamp.com
ABOUT EUROPEAN NETID FOUNDATION
The European netID Foundation was founded in March 2018 by Mediengruppe RTL Deutschland, ProSiebenSat.1 and United Internet with the brands WEB.DE and GMX. With an independent market solution, the foundation supports Internet offerings of all industries in implementing the new European data protection law and has created the open login standard netID for this purpose. The initiators of the foundation together reach around 50 million unique users every month and together have more than 38 million active accounts. The foundation is explicitly open for further partners and other initiatives. Further information is available at www.enid.eu.
“We are proud that our netID identifier is supported by Xandr’s end-to-end platform. This gives content providers in Europe the possibility to easily deliver personalized advertising in compliance with data protection regulations and across devices,” says Sven Bornemann, CEO of the European netID Foundation. “As well, we are very much looking forward to our partnership and warmly welcome Xandr’s Thomas Mendrina to the Publishing/Ad Sales advisory board of the European netID Foundation.”
ABOUT UNIFIED ID 2.0
Unified ID 2.0 is a next-generation identity solution that is an open-source digital framework. With initial development led by The Trade Desk, Unified ID 2.0 is the result of broad collaboration among publishers, buyers and technology providers across the industry. It serves as an alternative to third-party cookies that aims to improve consumer transparency, privacy and control, while preserving the value exchange of relevant advertising across channels and devices.
Prebid.org, the independent organization designed to ensure and promote fair and transparent marketplaces across the industry, has agreed to serve as operator of Unified ID 2.0. Prebid.org will begin this role in the second half of this year.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005390/en/
Contact information
Xandr
Kathryn Foster
kathryn.foster@xandr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
